This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waites, K. B.
Right arrow Articles by Kenny, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waites, K. B.
Right arrow Articles by Kenny, G. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2571-2573, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Mycoplasma hominis to Six Fluoroquinolones as Determined by E Test

Ken B. Waites,1,2,* Kay C. Canupp,2 and George E. Kenny3

Departments of Pathology1 and Physical Medicine and Rehabilitation,2 University of Alabama at Birmingham, Birmingham, Alabama, and Department of Pathobiology, University of Washington School of Public Health, Seattle, Washington3

Received 4 January 1999/Returned for modification 29 April 1999/Accepted 4 August 1999

Twenty isolates of Mycoplasma hominis were tested for their susceptibility to six fluoroquinolones by the E test. The MICs at which 90% of the isolates were inhibited (in micrograms per milliliter) were as follows: sparfloxacin, 0.031; clinafloxacin, moxifloxacin, and trovafloxacin, 0.063; levofloxacin, 0.25; and ciprofloxacin, 0.5. Increasing the amount of inoculum or incubation in CO2 elevated MICs by <= 1 dilution. E tests produce fluoroquinolone MICs comparable to those obtained by agar and microbroth dilution for M. hominis.

* Corresponding author. Mailing address: Department of Pathology WP 230, University of Alabama at Birmingham, Birmingham, AL 35233. Phone: (205) 934-0578. Fax: (205) 975-4468. E-mail: waites{at}path.uab.edu.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2571-2573, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 3973-3975 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Bing, X., Duffy, L. B. (2003). In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 161-165 [Abstract] [Full Text]  
  • Bebear, C. M., Renaudin, H., Bryskier, A., Bebear, C. (2000). Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas. Antimicrob. Agents Chemother. 44: 1980-1982 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»